about
Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitorsAntimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosisPotent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-PolN348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistanceThe NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytesContraction of the type I IFN locus and unusual constitutive expression of IFN-α in batsIdentification of diverse full-length endogenous betaretroviruses in megabats and microbatsDiscovery of retroviral homologs in bats: implications for the origin of mammalian gammaretrovirusesSPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humansStructure activity relationship of dendrimer microbicides with dual action antiviral activityHIV-1 infection of T cells and macrophages are differentially modulated by virion-associated Hck: a Nef-dependent phenomenonDimerization of human immunodeficiency virus type 1 reverse transcriptase as an antiviral target.Phosphatidylethanolamine binding is a conserved feature of cyclotide-membrane interactions.Identification of diverse groups of endogenous gammaretroviruses in mega- and microbats.Analysis of the contribution of reverse transcriptase and integrase proteins to retroviral RNA dimer conformation.N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutationsN348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutationsMutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer.Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring.Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules.Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1.Decoding the membrane activity of the cyclotide kalata B1: the importance of phosphatidylethanolamine phospholipids and lipid organization on hemolytic and anti-HIV activitiesSilent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations.The effect of NNRTIs on HIV reverse transcriptase dimerization.Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening.Fragment Based Strategies for Discovery of Novel HIV-1 Reverse Transcriptase and Integrase Inhibitors.Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptaseZidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.The packaging and maturation of the HIV-1 Pol proteins.Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.Bats and Rodents Shape Mammalian Retroviral Phylogeny.N348I in HIV-1 reverse transcriptase counteracts the synergy between zidovudine and nevirapine.Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase.Virological significance, prevalence and genetic basis of hypersusceptibility to nonnucleoside reverse transcriptase inhibitors.Biology of mucosally transmitted sexual infection-translating the basic science into novel HIV intervention: a workshop summary.Host-pathogen interactions of retroviruses.No association between XMRV or related gammaretroviruses in Australian prostate cancer patients.Vaginal concentrations of lactic acid potently inactivate HIVThe human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.
P50
Q24652511-46738111-4A6F-46AB-A12D-6AE8E97DA527Q28081831-E09610D3-53CC-4942-8BAE-C47F0B295882Q28469069-06E91F12-DA9F-47DF-B901-079AC6D80BC9Q28471689-65F45397-CFCD-4C64-A6CE-8CC65F7C1FDDQ28486204-154BC4B0-678B-4E15-9F73-278F9C4AF894Q28602705-561B05DD-C256-49D6-AEB0-38589F4B79A9Q28709205-46671845-7192-4E37-BB7A-EE8009A48BF5Q28730771-BA66A865-F1AD-44F5-9C86-8D49A7512CB1Q28740364-6EB35E6A-59E7-4C98-AD05-1EF93EF50CE2Q28749596-FEFB905C-F397-4EA1-ADFA-82651E3281EAQ30009553-6B642727-273A-4AB7-BF0F-C9D16C2D9691Q30354578-4868F84D-2CD0-4FC8-8437-F23007C118E5Q30525336-AADFCBF1-F197-4AE7-9EDD-EFC2ADFD196FQ31064298-B21FD55F-5530-4796-87DC-68017D2C04B5Q33780519-A15E4DB2-DC3D-405D-9164-BCE9F9360758Q33867773-CFBB3083-BCF4-4A35-96E0-7B6D6E585AD7Q33869951-CA2DE695-04DB-42BA-AE85-A349C8ED6F43Q33911895-BF249559-9343-450C-BC98-BA3B7180552AQ34413912-C26CBB7A-F471-48AF-BA62-94964E00A12AQ34853625-82BC9CC6-D9E5-4277-8AB9-B66790915A9FQ34976859-46FF22D7-640D-4C31-8BF7-AC438C2E0074Q35045703-8A4B6A4A-0B7D-4CCA-B201-4E4BCDF4657EQ35085127-4DDC28AE-78B2-42D2-89C3-D93F65E5B7A1Q35237036-363345FA-C183-435A-9EF2-06430100E8E8Q35543281-0BE40751-4B02-4AB9-AF3C-C544354FCC9FQ35650700-8F1DE962-9212-4A53-B153-38419291A6B1Q35760683-34DC6C4A-420F-4E5F-A4DA-8A549941D979Q35769639-8E131BE9-504D-4899-B504-AEA7B6E3F705Q35870930-638F5CB1-F258-4C27-9DED-15C63404C410Q36002732-D2A8AED6-6D14-455B-8EDD-BFB33E985FBBQ36200266-572DFC50-2AD9-4910-89C6-4925564E4459Q36262498-7619B21C-67F7-41EB-982E-911A62313B24Q36279266-E9F829A8-EB9E-4C54-B090-C1CA607318A3Q36297904-BD02E8B0-8869-4438-8AA5-B2CE443A2C5CQ36334217-610A6871-F375-441E-ABFE-B3BD6F274257Q36358993-0B2FB338-2D4C-490F-8150-5B058AE4BFEDQ36369324-F7763CB3-C283-4240-BC84-FCC3814AFE63Q36575553-D1B58F0B-8FAF-4800-93FE-9F8F2008E76DQ37095477-6C52D99C-3E79-4813-A49B-1E2B3D40A2E5Q37145329-BF4C461C-E7D4-4DD2-9747-19ABF2043420
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gilda Tachedjian
@ast
Gilda Tachedjian
@en
Gilda Tachedjian
@es
Gilda Tachedjian
@nl
type
label
Gilda Tachedjian
@ast
Gilda Tachedjian
@en
Gilda Tachedjian
@es
Gilda Tachedjian
@nl
prefLabel
Gilda Tachedjian
@ast
Gilda Tachedjian
@en
Gilda Tachedjian
@es
Gilda Tachedjian
@nl
P106
P108
P21
P31
P496
0000-0002-7733-7037